Cancer biospecimen collection study for immunotherapy patients
Part of Cancer, Digestive system, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This study collects samples (like tissue biopsies and imaging information) from people with certain cancers who are starting anti–PD-1/PD-L1 immunotherapy. It helps researchers gather material to study how these treatments work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have one of these cancers: head/neck squamous cell, NSCLC, SCLC, bladder (urothelial), stomach/GE junction adenocarcinoma, cervical, esophageal squamous, triple-negative breast, liver (hepatocellular), kidney (renal cell), or colorectal
- You have received or will receive at least one dose of an anti–PD-1/PD-L1 immunotherapy (a cancer medicine that targets PD-1 or PD-L1)
- You have had or will have a tumor biopsy before starting the anti–PD-1/PD-L1 treatment
- You have had or will have tumor imaging (such as CT or MRI) before starting the anti–PD-1/PD-L1 treatment
- You can give consent, are 18 or older, and can read and speak English well enough to understand the study
- There is enough leftover tissue (or tissue you can provide) for the study’s sample needs
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at what makes some cancers more “noticeable” to the immune system. It may help researchers design better future immunotherapy by collecting information (often including blood samples) from people with different cancers.
This study collects and analyzes medical information (and sometimes tissue samples) to help personalize treatment plans for advanced non-small-cell lung cancer using immunotherapy. It may help researchers find which people benefit most and how treatment can be better matched to each patient.
This study collects tumor and related samples from people with certain newly diagnosed cancers. Researchers use these samples to better understand how cancer cells, the surrounding tissue, and the immune system interact, which may guide better future treatments.
This study aims to deeply analyze immune cells and tumor cells in the blood and tumors of cancer patients. It may help researchers better understand how the immune system interacts with cancer.
This study collects blood and tumor tissue samples to analyze biological markers in patients with advanced head and neck squamous cell carcinoma before starting immunotherapy. The goal is to better understand how these markers relate to treatment response.
This study looks at how your body reacts to immunotherapy drugs (like PD-1 or CTLA-4 blockers) when given for the first time. It aims to predict side effects and help make treatment safer.
Hear when a new Lung Cancer, Nonsmall Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.